The United Kingdom's Competition and Markets Authority has opened an investigation into the acquisition. What happens now?
News & Analysis: Pacific Biosciences of California
The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.
A 71% premium for a less-successful competitor may seem excessive, but timing is everything.
Find out which of these stocks got a buyout bid.
A $1.2 billion acquisition of the gene-sequencing company sends its shares into orbit.
A pending buyout by Illumina overshadows the gene-sequencing company's third-quarter performance.
The gene sequencing company plans to tap investors for more cash.
Pacific Biosciences thinks platform upgrades will cut its Sequel machines' DNA sequencing costs 92% by 2019, opening a $2.5 billion market opportunity in 2022.
Shipments delayed in the first quarter were installed in the second quarter, boosting the gene-sequencing company's revenue.
Investors are taking a cautious stance ahead of earnings next week and an ongoing trade spat with China.